Related Experiment Video
Updated: Jun 26, 2026
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
Mutational spectrum and prognosis in Chinese patients with prefibrotic primary myelofibrosis
Chi-Keung Cheng1, Jennifer W Y Lai2, Yuk-Lin Yung1
1Blood Cancer Cytogenetics and Genomics Laboratory Department of Anatomical and Cellular Pathology Prince of Wales Hospital The Chinese University of Hong Kong Hong Kong China.
Abstract:
Prefibrotic primary myelofibrosis (Pre-PMF) has been classified as a separate entity of myeloproliferative neoplasms (MPNs). Pre-PMF is clinically heterogeneous but a specific prognostic model is lacking. Gene mutations have emerged as useful tools for stratification of myelofibrosis patients. However, there have been limited studies comprehensively investigating the mutational spectrum and its clinicopathological significance in pre-PMF subjects. In this study, we addressed these issues by profiling the mutation status of 141 genes in 172 Chinese MPN patients including 72 pre-PMF cases. Our findings corroborated the clinical/molecular distinctiveness of pre-PMF and suggested a refined risk classification strategy for this entity.
Insights
Prefibrotic primary myelofibrosis (Pre-PMF) is a distinct myeloproliferative neoplasm lacking a prognostic model. Gene mutation profiling in Chinese patients revealed distinct molecular features, suggesting a refined risk classification for Pre-PMF.
Area of Science:
- Hematology
- Oncology
- Genetics
Background:
- Prefibrotic primary myelofibrosis (Pre-PMF) is recognized as a distinct entity within myeloproliferative neoplasms (MPNs).
- Pre-PMF exhibits significant clinical heterogeneity, yet lacks a specific prognostic model for patient stratification.
- Comprehensive investigation into the mutational landscape and its clinicopathological relevance in Pre-PMF is limited.
Purpose of the Study:
- To comprehensively profile gene mutations in Chinese patients with MPNs, focusing on pre-PMF.
- To investigate the clinicopathological significance of identified gene mutations in pre-PMF.
- To explore the potential for a refined risk classification strategy in pre-PMF based on molecular findings.
Main Methods:
- Conducted mutational profiling of 141 genes using next-generation sequencing.
- Analyzed a cohort of 172 Chinese MPN patients, including 72 with pre-PMF.
- Correlated gene mutation status with clinical and pathological features.
Main Results:
- Confirmed the clinical and molecular distinctiveness of pre-PMF compared to other MPNs.
- Identified a spectrum of gene mutations relevant to pre-PMF pathogenesis and progression.
- Demonstrated the utility of molecular profiling for stratifying pre-PMF patients.
Conclusions:
- Gene mutation analysis provides valuable insights into the distinct biology of pre-PMF.
- Molecular profiling can enhance risk stratification for pre-PMF patients.
- Findings support the development of a refined prognostic model for pre-PMF.
